Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Sera Prognostics, Inc. (NASDAQ: SERA), a Salt Lake City–based health diagnostics company focused on precision pregnancy care and preterm birth risk prediction. As a public company, Sera files annual, quarterly, and current reports that describe its financial condition, operations, and key clinical and commercial developments.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of Sera’s business, including its focus on the PreTRM® Test, a blood-based biomarker test for individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies. These filings typically include information on revenues, operating expenses, research and development activities, and risk factors relevant to the company’s diagnostics business.
Current reports on Form 8-K document material events such as the release of quarterly financial results and significant clinical milestones. Recent 8-K filings reference press releases announcing second and third quarter financial results and the acceptance of the PRIME study for publication in a peer-reviewed journal. These filings help readers track how clinical evidence, such as the PRIME randomized controlled trial, connects to Sera’s commercial and strategic plans.
Users can also monitor Form 4 and other insider transaction filings, when available, to see reported trades by directors, officers, or significant shareholders. Stock Titan’s tools surface new SERA filings as they appear in the SEC’s EDGAR system and provide AI-powered summaries to explain key points, highlight important sections in lengthy documents, and make it easier to understand how disclosures about the PreTRM Test, payer engagement, and financial performance may relate to the company’s overall trajectory.
Form 144 notice (SERA) records a proposed sale of 222 Class A common shares through Morgan Stanley Smith Barney on 09/05/2025 with an aggregate market value of 744. The filing states these shares were acquired the same day via restricted stock unit vesting and lists total shares outstanding as 38,061,868. The filer disclosed three sales in the past three months by Mansoor Raza Mirza: 107 shares on 06/06/2025 for gross proceeds 169; 234 shares on 07/07/2025 for gross proceeds 552; and 225 shares on 08/05/2025 for gross proceeds 563. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Sera Prognostics insider sale by Chief Data Officer — The reporting person, Paul Kearney, executed a sale of 1,458 shares of Class A common stock on 09/02/2025 at a reported price of $3.49 per share. After the sale, the filing shows the reporting person beneficially owns 176,940 shares. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2025, and the Form 4 was submitted by an attorney-in-fact.
Sera Prognostics, Inc. (SERA) Form 144 notice reports a proposed sale of 1,458 common shares by an insider through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The filing shows an aggregate market value of $4,709.34 for the proposed sale and lists 37,094,109 shares outstanding. The shares to be sold were acquired as restricted stock units on 05/15/2024. The filer also reported three recent sales during the past three months by the same person totaling 18,313 shares for gross proceeds of $55,139.26 on 06/10/2025, 08/08/2025, and 08/29/2025.
Sera Prognostics insider sale reported. Paul Kearney, Chief Data Officer, filed a Form 4 disclosing a sale of 10,542 shares of Class A common stock on 08/29/2025 at a reported price of $3.49 per share. After the transaction Mr. Kearney beneficially owned 178,398 shares, held directly. The filing states the trade was executed under a Rule 10b5-1 trading plan adopted May 21, 2025, indicating the sale was preplanned rather than a discretionary transaction. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/02/2025.
Sera Prognostics (SERA) Form 144 notice reports a proposed sale of 10,542 common shares with an aggregate market value of $32,469.36 through Morgan Stanley Smith Barney on NASDAQ, with an approximate sale date of 08/29/2025.
The shares were acquired as restricted stock units from the issuer on 02/06/2024. The filer also reported recent disposals in the past three months: 6,460 shares sold on 08/08/2025 for $16,408.40 and 1,311 shares sold on 06/10/2025 for $1,940.28. The filer certifies no undisclosed material adverse information and includes standard Notice and signature statements.
Harrison Robert Gardner, Chief Information Officer of Sera Prognostics, Inc. (SERA), reported a sale of 6,000 shares of Class A common stock on 08/20/2025 under a pre-existing Rule 10b5-1 trading plan adopted May 21, 2025. The shares were sold at a weighted average price of $2.22, with executed prices ranging from $2.17 to $2.25. After the sales, the reporting person beneficially owned 102,577 shares directly. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on the same date.
Form 144 notice for SERA (Sera Prognostics, Inc.) reporting proposed sale of common stock by Robert Gardner Harrison. The filing lists 6,000 shares to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $13,500.00 and an approximate sale date of 08/20/2025. The shares were acquired as Restricted Stock Units on 02/06/2024. The issuer's outstanding shares are shown as 37,094,109. The filing also discloses recent sales by the same person: 5,962 shares sold on 08/08/2025 for $15,143.48 and 667 shares sold on 06/10/2025 for $987.16. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.
RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah filed an amended Schedule 13G reporting no beneficial ownership of Sera Prognostics, Inc. (SERA) Class A common stock as of June 30, 2025. The filing lists each reporting person’s citizenship and principal business address and states that each holds 0 shares and 0.0% of the class. The filers expressly disclaim status as a group and certify the securities were not acquired to influence control of the issuer. A joint filing agreement is incorporated by reference.
Sera Prognostics (SERA) reporting person Zhenya Lindgardt, who serves as Chief Executive Officer and Director, reported a mandated sale to satisfy tax withholding on vested restricted stock units. On 08/08/2025 the reporting person sold 8,571 shares in a block trade at a weighted average price of $2.54; individual trade prices ranged from $2.28 to $2.73. The Form states the sale was required by the issuer's election to use "sell to cover" and was not a discretionary transaction by the reporting person.
Following the sale the reporting person beneficially owned 832,294 shares directly. The Form 4 was executed by an attorney-in-fact and filed with the SEC on 08/11/2025. No derivative transactions were reported in this filing.
Insider sale to cover RSU tax withholding. Kearney Paul, Chief Data Officer of Sera Prognostics (SERA), sold 6,460 shares of Class A common stock on 08/08/2025 as a mandated sell-to-cover to satisfy tax withholding associated with RSU vesting. The filing states this was not a discretionary transaction by the reporting person. The block trade produced a weighted-average price of $2.54, with transaction prices ranging from $2.28 to $2.73.
The reporting person continues to directly beneficially own 188,940 shares. The filer notes it will provide a per-price breakdown of the block trade to the SEC or other parties upon request. No derivative transactions were reported in this filing.